Current and Future PET imaging for multiple myeloma

M Ishibashi, M Takahashi, T Yamaya, Y Imai - Life, 2023 - mdpi.com
Positron emission tomography (PET) is an imaging modality used for the noninvasive
assessment of tumor staging and response to therapy. PET with 18F labeled …

First-in-Humans Evaluation of Safety and Dosimetry of 64Cu-LLP2A for PET Imaging

R Laforest, A Ghai, TJ Fraum, R Oyama… - Journal of Nuclear …, 2023 - Soc Nuclear Med
There remains an unmet need for molecularly targeted imaging agents for multiple myeloma
(MM). The integrin very late antigen 4 (VLA4), is differentially expressed in malignant MM …

Comparison of a Series of 68Ga-Labeled DOTA-LLP2A Conjugates for Positron Emission Tomography Imaging of Very Late Antigen-4 in Melanoma

P Zhou, Y Wu, G Han, J Jiang, H Wang… - Molecular …, 2025 - ACS Publications
Melanoma, with its steadily rising global incidence, is characterized by high invasiveness,
leading to poor prognosis in advanced stages. There remains an unmet clinical need for the …

Albumin-Binding Lutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma

MD Pun, F Gallazzi, KV Ho, L Watkinson… - Molecular …, 2024 - ACS Publications
Very late antigen-4 (VLA-4) is a transmembrane integrin protein that is highly expressed in
aggressive forms of metastatic melanoma. A small-molecule peptidomimetic, LLP2A, was …

Imaging Very Late Antigen-4 on MOLT4 Leukemia Tumors with Cysteine Site-Specific 89Zr-Labeled Natalizumab Immuno-Positron Emission Tomography

M Kim, KH Jung, JL Kim, HJ Koo, HJ Jung… - Molecular …, 2024 - ACS Publications
Very late antigen-4 (VLA4; CD49d) is a promising immune therapy target in treatment-
resistant leukemia and multiple myeloma, and there is growing interest in repurposing the …

Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma

SA Holstein, F Asimakopoulos, AK Azab… - … and cellular therapy, 2022 - Elsevier
ABSTRACT The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma
Intergroup conducted a workshop on Immune and Cellular Therapy in Multiple Myeloma on …

Proceedings from the Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Immune and Cellular Therapy in Multiple Myeloma.

SA Holstein, F Asimakopoulos, AK Azab… - … and Cellular Therapy, 2022 - europepmc.org
Abstract The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma
Intergroup conducted a workshop on Immune and Cellular Therapy in Multiple Myeloma on …